The failure of Opthea’s much-heralded eye treatment has already caused considerable pain for investors. The ASX-listed biotech counted Phil King’s Regal Partners as its biggest shareholder, with a 30 per cent stake.
But there are plenty of others who are facing big losses. Opthea warned the failure of a late-stage trial of its OPT-302 treatment would trigger obligations to pay back development funding to the likes of The Carlyle Group, which would almost certainly render the company insolvent.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.